Integra LifeSciences has announced the launch of its Integra wound matrix (thin), a collagen-glycosaminoglycan wound matrix that maintains and supports a healing environment for wound management.
The company has obtained 510(k) approval from the US Food and Drug Administration (FDA) for the Integra wound matrix (thin) and the company expects to begin a full market release in the US in April 2014.
The newest skin product is available in a variety of sizes and is intended for one-time use. Terminally sterilized, Integra wound matrix (thin) is conveniently stored at room temperature and has a two-year shelf life.
It may be used for second degree burns, partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds.
In addition, it may be used for surgical wounds (donor sites/grafts, post-Moh’s surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, skin tears) and draining wounds.
Integra Extremity Reconstruction vice president and general manager William Weber noted that the Integra wound matrix (thin) is a very exciting opportunity for the company.
"Our new, thinner product has approximately half the thickness of IntegraWound Matrix and reflects our commitment to offer surgeons enhanced treatment options. The thinner matrix can be applied to complex anatomical sites that require a more conformable graft," Weber added.
Integra LifeSciences will feature the Integra wound matrix (thin) at the American Burn Association Annual Meeting, 25 March to 28 March 2014, in Boston, Massachusetts.